Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis

2007900 citationsJournal Articlebronze Open Access

Authors

Kenneth G. Saag · University of Alabama at Birmingham

Elizabeth Shane · Columbia University

Steven Boonen · KU Leuven

Fernando Marín · Eli Lilly (United States)

David W. Donley · Eli Lilly (United States)

Kathleen A. Taylor · Eli Lilly (United States)

G. P. Dalsky ·

Abstract

Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate. (ClinicalTrials.gov number, NCT00051558 [ClinicalTrials.gov].).

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Bone Metabolism and Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 20, pp. 2028-2039

DOI: 10.1056/nejmoa071408

Field-Weighted Citation Impact: 44.92